Text Size

An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital
ClinicalTrials.gov Identifier:
NCT01502579
First received: December 29, 2011
Last updated: December 17, 2012
Last verified: December 2012
History of Changes
  Purpose

The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.


Condition
IgA Nephropathy

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy

Further study details as provided by Guangdong General Hospital:

Primary Outcome Measures:
  • glomerular filtration rate decline or end-stage renal disease or doubling of serum creatinine [ Time Frame: after the biopsy ] [ Designated as safety issue: No ]

Estimated Enrollment: 560
Study Start Date: September 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The population from which the cohort will be selected is these who have received renal biopsy in Guangdong General Hospital

Criteria

Inclusion Criteria:

  • biopsy-proven IgA nephropathy;

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01502579

Locations
China, Guangdong
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Guangdong General Hospital
Investigators
Principal Investigator: Wei Shi, MD,PhD Guangdong General Hospital
  More Information

No publications provided

Responsible Party: Wei Shi, Professor, Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT01502579     History of Changes
Other Study ID Numbers: GGH201106
Study First Received: December 29, 2011
Last Updated: December 17, 2012
Health Authority: China: Ethics Committee

Keywords provided by Guangdong General Hospital:
IgA nephropathy

Additional relevant MeSH terms:
Glomerulonephritis, IGA
Kidney Diseases
Glomerulonephritis
Nephritis
 Urologic Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013